People with aphasia—a brain disorder affecting about a million people in the U.S.—struggle to turn their thoughts into words and comprehend spoken language.

We spend billions searching for the cures to chronic illnesses while neglecting research that could make the daily lives of ...

A drug for treating diabetes similar to popular weight-loss medicines such as Ozempic did not show any benefits for people ...

The Google cofounder has donated more than $1.5 billion to Parkinson’s research. Now, as he takes on autism, he’s also ...

People with early-onset Parkinson’s face challenges different from those with traditional late-onset Parkinson’s.

CyberKnife radiosurgery is a 15-minute outpatient procedure that requires no anesthesia or hospital admission, offering a non-invasive alternative to traditional surgeries for treating Parkinson’s ...

Boosting communication between the spinal nerves and the muscles using the spinal cord stimulation reverses spinal muscle atrophy (SMA) progression and could be applied to other motoneuron diseases, ...

A final-stage study has found that exenatide, a GLP-1 drug used to treat Type 2 diabetes, showed no benefit in slowing the progression of Parkinson's disease. The 96-week trial, published in The ...

WEDNESDAY, Feb. 5, 2025 (HealthDay News) -- Hopes that GLP-1 drugs such as Ozempic and Wegovy could help slow Parkinson's ...

The GLP-1 drug, exenatide, has no positive impact on the movement, symptoms or brain imaging of people with Parkinson's ...

Americans will soon have access to an infusion device that provides round-the-clock effective relief of Parkinson's disease.

Traditional deep brain stimulation surgery can take up to 10 hours to complete, with the patient wide awake. This robotic ...